Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756 for Inflammatory Diseases, Including Atopic Dermatitis

Recludix Pharma announced the nomination of its lead development candidate, REX-8756, an oral, reversible, and highly selective STAT6 inhibitor designed to address a wide range of type 2 inflammatory diseases, including atopic dermatitis.